Step therapy by Medicare Advantage plans was also associated with more injections, although that result fell short of meeting statistical significance standards.

A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

In a study in mice, a wireless implant was able to release glucagon as an emergency treatment for hypoglycemia, a serious complication of Type 1 diabetes.

More than 60 companies pledged to improve healthcare technology during a White House “Make Health Tech Great Again” event hosted as part of the Centers for Medicare & Medicaid Services Health Tech ...

Patients with advanced age-related macular degeneration can safely be treated with a combination of anti-VEGF and anti-complement therapies, according to the results from a real-world study, which was ...

New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy patients, according to Robert Goldberg, M.D., MBA, of the Bay Area Retina ...

Extension study results suggest dosing intervals of 20 weeks or more for Eylea HD for diabetic macular edema.

New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

The problem is not too much consolidation. Mandating transparency rules could be counterproductive. The worry about spread pricing is beside the point. We don’t ask companies in other sectors how much ...

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and fewer adverse events than povidone-iodine.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea HD in patients with neovascular (wet) age-related macular degeneration.